688363.SHG Bloomage Biotechnology Corp Ltd
- Market cap
- CNY 16.9B
- P/E
- 73.0x
- P/B
- 2.33x
- ROE
- 3.5%
- Dividend yield
- 0.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688363.SHG undervalued?
Graham number688363.SHG trades 174.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bloomage Biotechnology Corp Ltd fundamental analysis
No fundamental analysis for Bloomage Biotechnology Corp Ltd yet.
Bloomage Biotechnology Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited develops, produces, and sells bioactive materials. It offers beauty and care products under the Hymagic-VCHA VC Hylauronic Acid; Biomeet-MarineDNA; Bioyouth-SPG Schizophyllan Gel; Hymagic-GluHA; Bloomsurfact EncapCare RP; Bloomsurfact Sodium Surfactin; Hybloom Minitrue; Bioyouth-EGT Pure Ultrapure Ergothioneine; miniHA HA-Oligo degraded by hyaluronidase; microHA Super Active Hyaluronic Acid; Hymagic-AcHA Sodium Acetylated Hyaluronat…
Full company profileBloomage Biotechnology Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bloomage Biotechnology Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 733M | 818M | 1.26B | 1.89B | 2.63B | 4.95B | 6.36B | 6.08B | 5.37B | 4.20B | 3.46B |
| Gross Profit | 563M | 612M | 1.00B | 1.50B | 2.12B | 3.83B | 4.88B | 4.42B | 3.89B | 2.95B | 2.30B |
| Operating Income | 320M | 284M | 524M | 700M | 757M | 906M | 1.14B | 708M | 216M | 459M | 265M |
| EBITDA | 338M | 321M | 529M | 729M | 740M | 867M | 1.12B | 775M | 465M | 698M | 260M |
| Net Income | 269M | 222M | 424M | 586M | 646M | 782M | 971M | 593M | 174M | 292M | 248M |
| EPS | 0.73 | 0.60 | 0.97 | 1.22 | 1.35 | 1.62 | 2.02 | 1.23 | 0.36 | 0.61 | 0.52 |
| Balance Sheet | |||||||||||
| Total Assets | 1.68B | 1.88B | 2.07B | 4.97B | 5.72B | 7.50B | 8.68B | 8.47B | 8.66B | 8.69B | 8.75B |
| Total Liabilities | 424M | 245M | 354M | 422M | 623M | 1.80B | 2.00B | 1.49B | 1.82B | 1.58B | 1.61B |
| Shareholders' Equity | 1.26B | 1.64B | 1.72B | 4.55B | 5.02B | 5.70B | 6.63B | 6.94B | 6.81B | 7.09B | 7.11B |
| Cash & Short-term Investments | 558M | 727M | 854M | 3.00B | 2.11B | 2.65B | 2.14B | 1.31B | 749M | 995M | 825M |
| Total Debt | 220M | - | 40.0M | - | 89.3M | 300M | 390M | 208M | 268M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 242M | 343M | 442M | 365M | 705M | 1.28B | 635M | 700M | 565M | 627M | - |
| Capital Expenditure | 19.9M | 46.0M | 168M | 450M | 763M | 784M | 696M | 1.03B | 721M | 326M | 357M |
| Free Cash Flow | 222M | 297M | 274M | -85.3M | -57.7M | 492M | -61.2M | -331M | -157M | 302M | 416M |
| Ratios | |||||||||||
| ROE | 21.4% | 13.6% | 24.7% | 12.9% | 12.9% | 13.7% | 14.6% | 8.5% | 2.6% | 4.1% | 3.5% |
| ROA | 16.0% | 11.8% | 20.5% | 11.8% | 11.3% | 10.4% | 11.2% | 7.0% | 2.0% | 3.4% | 2.8% |
| Net Profit Margin | 36.8% | 27.2% | 33.6% | 31.1% | 24.5% | 15.8% | 15.3% | 9.8% | 3.2% | 7.0% | 7.2% |
| Debt to Equity | 0.17x | - | 0.02x | - | 0.02x | 0.05x | 0.06x | 0.03x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bloomage Biotechnology Corp Ltd dividends
- Dividend yield
- 0.33%
- Forward dividend
- 0.19 CNY
- Payout ratio
- 19.2%
- Ex-dividend date
- Jul 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 56.1M | 0.12 | 19.2% |
| 2024 | CNY 186M | 0.38 | 106.7% |
| 2023 | CNY 305M | 0.63 | 51.6% |
| 2022 | CNY 236M | 0.49 | 24.3% |
| 2021 | CNY 197M | 0.41 | 25.2% |
| 2020 | CNY 178M | 0.37 | 27.5% |
| 2019 | CNY 178M | 0.37 | 30.3% |
| 2018 | CNY 1.01B | 2.31 | 238.2% |
| 2017 | CNY 15.8M | 0.04 | 7.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bloomage Biotechnology Corp Ltd
- Insiders 61.83%
- Institutions 9.66%
- Public & others 28.51%
- Shares outstanding 482M
- Free float 193M
Bloomage Biotechnology Corp Ltd company profile
- Company name
- Bloomage Biotechnology Corp Ltd
- Ticker
- 688363.SHG
- ISIN
- CNE100003NL9
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 3,656
- Fiscal year end
- December
- Address
- No. 678 Tianchen Street, Jinan, China, 250101
- Phone
- 86 531 8268 5998
- Website
- bloomagebioactive.com
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited develops, produces, and sells bioactive materials. It offers beauty and care products under the Hymagic-VCHA VC Hylauronic Acid; Biomeet-MarineDNA; Bioyouth-SPG Schizophyllan Gel; Hymagic-GluHA; Bloomsurfact EncapCare RP; Bloomsurfact Sodium Surfactin; Hybloom Minitrue; Bioyouth-EGT Pure Ultrapure Ergothioneine; miniHA HA-Oligo degraded by hyaluronidase; microHA Super Active Hyaluronic Acid; Hymagic-AcHA Sodium Acetylated Hyaluronate; Hymagic-4D 4D Hyaluronic Acid; Hybloom Zinc Hyaluronate; Hybloom Sodium Hyaluronate 1% Solution; Hybloom Sodium Hyaluronate; Hybloom Oligo Hyaluronic Acid; Hybloom Low Molecular Weight Sodium Hyaluronate; Hybloom Hydrolyzed Hyaluronic Acid; Hybloom High Molecular Weight Sodium Hyaluronate; Hyanutra-RH Hair Nourishing Shield; Hyafacto-PGA Super High Molecular Weight Sodium Polyglutamate; Hyafactor-PGA Sodium Polyglutamate; Hyafactor-NAG Acetyl Glucosamine; Hyacross TG100 Hyaluronic Acid Elastomer; Hyacolor Oil-dispersed Sodium Hyaluronate; Gabacare BL98T Aminobutyric Acid; cationHA-G and clear Substantive Sodium Hyaluronate; Bioyouth-Natto Natto Extract; Bioyouth-NANA N-Acetylneuraminic Acid; Bioyouth HT Silky Hyaluronic Acid; Bioyouth-EGT Pro Super Active Ergothione; Bioyouth-Brice Brown Rice Ferment Filtrate; Bioyouth-FCM Cordyceps Militaris Ferment Filtrate; Bioyouth-EGT Ergothioneine Complex; Bioyouth BLC Bluelight Care; Bioecto Ectoine; and Biobloom Microecobeauty brands. It also provides pharma and aesthetics; nutrition and health products under the Hyatrue; Bloomecto; Bloomcolla; BloomseaN; BloomStem; MitoEGT L-Ergothioneine; UltraHA J Sodium Hyaluronate; MitoPQQ Pyrroloquinoline Quinone Disodium; UltraHA-CWS Sodium Hyaluronate; HAPLEX Plus Sodium Hyaluronate; Gabarelax Gamma Aminobutyric Acid; UltraHA-GI-001 Special sodium hyaluronate for gut health; and Biovivid Collagen Peptide brands. The company was founded in 2000 and is based in Jinan, China.
Bloomage Biotechnology Corp Ltd management
7- Ms. Yan ZhaoChairman & CEO · born 1966
- Mr. Hui WangDeputy GM, CFO & Director · born 1983
- Mr. Jiajun GuoDeputy GM & Director · born 1975
- Mr. Yizheng LiDeputy GM, Secretary of the Board & Director · born 1984
- Mr. Mao Gong XiangDeputy General Manager · born 1984
- Tao TianAccounting Supervisor
- Ms. Yanli ShiChief Technology Officer of Raw Material R&D · born 1971